Kynurenine attenuates mitochondrial depolarization and neuronal cell death induced by rotenone exposure independently of AhR-mediated parkin induction in SH-SY5Y differentiated cells

Supplementation with L-kynurenine during in vitro maturation improves bovine oocytes developmental competence through its antioxidative action

Oxidative stress impairs the developmental potential of oocytes during in vitro maturation (IVM). L-kynurenine (L-KYN), an endogenous metabolite, exhibits antioxidant, anti-inflammatory and neuroprotective effects. This work aimed to evaluate the potential effects of L-KYN on bovine oocyte IVM and its mechanisms. Different concentrations of L-KYN (0, 10, 50, 100, and 200 μmol/L) were supplemented to bovine oocyte IVM medium. Results shown a notable enhancement in the oocyte maturation rate and the subsequent zygote cleavage and blastocyst formation rate when the L-KYN concentration reached 100 μmol/L. Further analysis revealed that this treatment effectively down-regulated expression levels of genes to cumulus cell apoptosis (Bax and Caspase3), up-regulated expression levels of genes to cumulus cell expansion (HAS2, PTX3, and PTGS2) and oocyte antioxidant (GPX4 and CAT). L-KYN supplementation also effectively increased glutathione (GSH) levels, promoted oocytes mitochondrial activity, enhanced DNA repairability, deceased reactive oxygen species (ROS) levels, and reduced apoptosis. In conclusion, adding 100 μmol/L of L-KYN to IVM medium could enhance bovine oocyte quality and the subsequent embryonic development. L-KYN could be a potential antioxidant supplement for bovine oocyte maturation in vitro.

Indoleamine 2,3-dioxygenase (IDO1) - Can dendritic cells and monocytes expressing this moonlight enzyme change the phase of Parkinson's Disease?

Parkinson's Disease (PD) is the second most common neurodegenerative disease where central and peripheral immune dysfunctions have been pointed out as a critical component of susceptibility and progression of this disease. Dendritic cells (DCs) and monocytes are key players in promoting immune response regulation and can induce the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) under pro-inflammatory environments. This enzyme with catalytic and signaling activity supports the axis IDO1-KYN-aryl hydrocarbon receptor (AhR), promoting disease-specific immunomodulatory effects. IDO1 is a rate-limiting enzyme of the kynurenine pathway (KP) that begins tryptophan (Trp) catabolism across this pathway. The immune functions of the pathway, which are extensively described in cancer, have been forgotten so far in neurodegenerative diseases, where a chronic inflammatory environment underlines the progression of the disease. Despite dysfunctions of KP have been described in PD, these are mainly associated with neurotoxic functions. With this review, we aim to focus on the immune properties of IDO1+DCs and IDO1+monocytes as a possible strategy to balance the pro-inflammatory profile described in PD. We also highlight the importance of exploring the role of dopaminergic therapeutics in IDO1 modulation to possibly optimize current PD therapeutic strategies.